Vivienne Cox - GlaxoSmithKline PLC Non-Executive Independent Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:6em;padding-top: 0px;;'>G</div>
GSK -- USA Stock  

Fiscal Quarter End: March 31, 2020  

Dr. Vivienne Cox, CBE, is NonExecutive Independent Director of the Company. Vivienne has wide experience of business gained in the energy, natural resources and publishing sectors. She also has a deep understanding of regulatory and government relationships. She worked for BP plc for 28 years, in Britain and continental Europe, in posts including Executive Vice President and Chief Executive of BPs gas, power and renewable business and its alternative energy unit. Vivienne was previously a NonExecutive Director of BG Group plc and Rio Tinto plc and Lead Independent Director at the UK Governments Department for International Development. Vivienne was appointed Commander of the Order of the British Empire in the 2016 New Year Honours for services to the UK Economy and Sustainability. Vivienne is Senior Independent Director of Pearson plc, a NonExecutive Director of Stena AB and Chairman of the Supervisory Board of Vallourec. She is an Advisory Board Member of the African Leadership Institute, Chair of Rosalind Franklin Institute, Vice President of the Energy Institute and a member of the advisory board of Montrose Associates. Vivienne sits on the Global Leadership Council of Sad Business School, Oxford and is Patron of the Hospice of St Francis.
Age: 59  Director Since 2017  Ph.D    
(44) 20 8047 7807  www.gsk.com

Management Efficiency

The company has 36.63 B in debt with debt to equity (D/E) ratio of 182.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. GlaxoSmithKline PLC has Current Ratio of 0.8 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Stephen SangerPfizer
Juan LucianoEli Lilly And Company
Catherine KlemaAllergan Plc
Nesli BasgozAllergan Plc
Ronald TaylorAllergan Plc
Wyllie CornwellPfizer
Erik FyrwaldEli Lilly And Company
Gerald StorchBristol Myers Squibb Company
Jose BaselgaBristol Myers Squibb Company
Paul RothmanMerck Company
Theodore SamuelsBristol Myers Squibb Company
Ian DavisJohnson Johnson
James KiltsPfizer
Anne MulcahyJohnson Johnson
Pierre LandoltNovartis AG
Helen HobbsPfizer
Srikant DatarNovartis AG
Lewis CampbellBristol Myers Squibb Company
Patricia RussoMerck Company
Christopher CoughlinAllergan Plc
James SmithPfizer

Company Summary

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.GlaxoSmithKline PLC (GSK) is traded on BATS Exchange in USA. It is located in 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom and employs 95,490 people. GlaxoSmithKline PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

GlaxoSmithKline PLC Leadership Team

Vindi Banga, Senior Independent Non-Executive DirectorView
Lynn Elsenhans, Independent Non-Executive DirectorView
Luke Miels, President - Global PharmaceuticalsView
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive DirectorView
Daniel Podolsky, Non-Executive Independent DirectorView
Emma Walmsley, Chief Executive Officer, Executive DirectorView
Luc Debruyne, President - Global VaccinesView
Andrew Witty, CEO, Executive DirectorView
Brian McNamara, Chief Executive Officer - GSK Consumer HealthcareView
Roy Anderson, Non-Executive Independent DirectorView
Philip Hampton, Independent Non-Executive DirectorView
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. CommitteeView
Vivienne Cox, Non-Executive Independent DirectorView
Bill Louv, Senior Vice President - Core Business ServicesView
Roger Connor, President - Global Manufacturing & SupplyView
Abbas Hussain, President Global PharmaceuticalsView
Phil Thomson, Senior Vice President - Global CommunicationsView
Judy Lewent, Non-Executive Independent DirectorView
Hans Wijers, Independent Non-Executive DirectorView
Stephanie Burns, Non-Executive Independent DirectorView
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. CommitteeView
Urs Rohner, Non-Executive Independent DirectorView
Marvinder Banga, Senior Non-Executive Independent DirectorView
Deryck Maughan, Senior Independent Non-Executive DirectorView
Jesse Goodman, Non-Executive Independent DirectorView
Laurie Glimcher, Non-Executive Independent DirectorView
Nick Hirons, Senior Vice President - Global Ethics and ComplianceView
James Ford, Senior Vice President General CounselView
Victoria Whyte, Company SecretaryView
Daniel Troy, Sr. VP and General CounselView
Shah Hussain, President - Europe, Japan & EMAPView
Manvinder Banga, Non-Executive DirectorView
David Redfern, Chief Strategy OfficerView
Patrick Vallance, President - Pharmaceuticals R&DView
Stacey Cartwright, Non-Executive Independent DirectorView
Regis Simard, President - Pharmaceutical Supply ChainView
Jonathan Symonds, Independent Non-Executive Chairman of the BoardView
Iain Mackay, Chief Financial Officer, Executive DirectorView
Karenann Terrell, Chief Digital & Technology OfficerView
Claire Thomas, Senior Vice President - Human ResourcesView

Stock Performance Indicators

Did you try this?

Run Price Ceiling Movement Now


Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Plese check Risk vs Return Analysis. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.